Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Panel Finds Little Support For Amyloid PET Imaging Changes

This article was originally published in The Pink Sheet Daily

Executive Summary

MEDCAC panel has low-to-intermediate confidence that there is enough evidence to show beta amyloid positron emission tomography imaging of the brain changes health outcomes. The vote does not bode well for the technology’s coverage proposal due in July.

You may also be interested in...



Lilly Submits New Amyvid Data For Medicare National Coverage Analysis

Physicians in study changed their diagnosis of whether a patient had Alzheimer’s in half of cases after receiving data from PET scans using Lilly’s beta amyloid detecting tracer Amyvid. Study findings were not available when Lilly first asked CMS to conduct the coverage analysis.

Louis Jacques On Coverage, Evidence And IDEs

Former CMS coverage director Louis Jacques talks about the strong future ahead he envisions for the Medicare coverage-with-evidence-development program and new coverage policies that will be implemented for investigational device exemption trials.

Reimbursement Briefs: Pfizer Joins Big Data Group; Part D Protected Classes; Wikipedia Partners With Cochrane Collaboration

Pfizer is among seven organizations joining the Optum Labs research collaborative; CMS Coverage and Analysis Group Director Louis Jacques moving to private sector, more news in brief.

Topics

Related Companies

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel